Protein (5)
Launched (5)
Human (5)
His Tag & Avi Tag (2)His Tag (3)
Biotin-labeled (1)Unconjugated (2)AF488 Labeled (1)PE Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT HLD-H52E6 | HEK293 | Unconjugated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Monomer, MALS verified) | ||||
HOT HLD-H52H7 | HEK293 | Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Tetramer Protein | ||||
HOT HLD-H82E9 | HEK293 | Biotinylated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Monomer, MALS verified) | ||||
HOT HLD-HP2H6 | HEK293 | PE-Labeled Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Tetramer Protein | ||||
HEK293 | Alexa Fluor™ 488-Labeled Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Monomer) |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| VVN-001 | VVN001; VVN-001 | Phase 3 Clinical | VivaVision Biotech Inc | Dry Eye Syndromes; Xerophthalmia | Details |
| P-28-R | P-28- R | Phase 1 Clinical | Canimguide Therapeutics | Head and Neck Neoplasms | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Odulimomab | Approved | Immunotech SAS | Antilfa | France | Graft vs Host Disease; Rejection of renal transplantation | null | 1997-01-01 | Rejection of renal transplantation; Graft vs Host Disease | Details |




